AlphAIAlphAI — Financial news for AI agents
investing.comNOV 22 min read$RXRX

Recursion Pharmaceuticals earnings matched, revenue topped estimates

Recursion Pharmaceuticals (RXRX) reported Q3 EPS of $-0.22, matching estimates, with revenue of $18.55M, exceeding the $12.98M consensus. The stock is up 20.44% over 3 months but down 29.60% year-over-year. Analysts have revised EPS estimates twice positively and once negatively in the last 90 days. The company's financial health is rated as 'fair performance' by InvestingPro.

Original reporting
investing.com
Published Nov 2, 2026, 9:48 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 2, 2026, 9:57 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$RXRX
Bullish
medium confidence
Mentioned
$RXRX
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$RXRXBullishMed
01

Why it matters

Traders can use the EPS and revenue surprise versus consensus to gauge whether the market should re-rate the name, but without guidance or margin/cash details the decision is likely limited to near-term positioning.

02

Market read

Revenue beat is the main incremental datapoint versus expectations; EPS was exactly in line, reducing the likelihood of a large re-rating absent forward signals.

03

What to watch

The piece omits forward guidance, cash balance, and operating expense trends, which are often the real drivers for biotech valuation after earnings.

Relevance 7/10Novelty 7/10Timing: after-hours earnings report (published 2026-11-02 21:48:57+00:00)

Background

The article summarizes Recursion Pharmaceuticals’ Q3 earnings versus consensus and notes recent stock performance and revision counts.

Company-level read

Ticker impact

$RXRXBullishMedium confidence
Context

Recursion Pharmaceuticals reported Q3 EPS of -0.22 in line with estimates and revenue of $18.55M versus $12.98M consensus.

Expected impact

Likely modest upward bias as the market prices the revenue beat, with EPS in-line limiting upside surprise.

Evidence & confidence

The article provides the quarter’s EPS and revenue versus consensus, but no guidance, margin detail, or forward outlook to confirm sustained upside.

Market effects

Sector

Biotech and clinical-stage software/analytics peers may see read-through on demand and monetization, but the article lacks sector-wide context.

Regional

Primarily US small/mid-cap biotech sentiment; no cross-region catalyst described.

Global

No global macro or international regulatory driver mentioned.

Counterpoint

What could challenge this read

A revenue beat with in-line EPS can still mask weaker profitability or higher operating costs, so the stock reaction may fade if investors focus on cash burn or guidance not provided here.

Key entities

  • company
    Recursion Pharmaceuticals

    NASDAQ-listed biotech company reporting Q3 EPS and revenue versus analyst consensus.

Read at source← All news

Related articles

NOV 2
$RXRXMedAI 9/10

Recursion Reports Third Quarter 2026 Financial Results and Extends Cash Runway; Highlights Positive Clinical Data in REC-4881 and REC-1245, Sanofi…

RECURSION PHARMACEUTICALS, INC. (RXRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Recursion Reports Third Quarter 2026 Financial Results and Extends Cash Runway; Highlights Positive Clinical Data in REC-4881 and REC-1245, Sanofi Development Candidate Option and Appointment of Fred Hassan as Chair • New Phase 2 REC-4881 data presented at CGA-IGC in

SEC EDGAR 8-K7 min
NOV 2
$RXRXMedAI 8/10

Recursion Reports Third Quarter 2026 Financial Results and Extends Cash Runway; Highlights Positive Clinical Data in REC-4881 and REC-1245, Sanofi Development Candidate Option and Appointment of Fred Hassan as Chair

Recursion (RXRX) reported Q3 2026 results, extending cash runway to 2029. REC-4881 showed deep, durable polyp burden reductions in FAP, with activity across the GI tract. REC-1245 demonstrated early clinical signals in cancer. Sanofi optioned a development candidate. Fred Hassan appointed as Chair. Company reiterated 2026 and 2027 cash operating expense guidance.

globenewswire.com7 min
NOV 2
$RXRXMedAI 8/10

Recursion reports positive Phase 2 data for FAP treatment

Recursion (RXRX) reported positive Phase 2 data for REC-4881, an oral MEK1/2 inhibitor for familial adenomatous polyposis (FAP). After 12 weeks, patients saw a 47% median reduction in polyp burden, with 85% remaining below baseline 12 weeks post-treatment. The safety profile was consistent with the MEK inhibitor class. Recursion aims to start a registrational trial in late 2027, with FDA Orphan Drug and Fast Track designations already secured.

investing.com2 min
NOV 2
$RXRXMedAI 8/10

Two patients each went from over 90 large polyps to one

Recursion (RXRX) reported positive Phase 2 data from the TUPELO trial of REC-4881, an oral MEK1/2 inhibitor for familial adenomatous polyposis (FAP). After 12 weeks, patients saw a 47% median reduction in polyp burden, with 85% remaining below baseline 12 weeks post-treatment. Two patients reduced their larger polyp counts from over 90 to one. No new safety signals were observed. The company plans to initiate a registrational trial in 2027, pending FDA discussions.

stocktitan.net2 min
OCT 28
$RXRXHighAI 8/10

RXRX Stock Jumps As Sanofi Deal And Trial Data Ignite AI Drug Story

Recursion Pharmaceuticals (RXRX) stock rose 7.04% on October 28, 2026, driven by positive clinical trial data, a Sanofi deal, and a $200M equity raise. The company reported encouraging results for REC-4881 and REC-1245, while Sanofi's option exercise brought total payments to $144M. RXRX has a market cap of $74.3M, a price-to-sales ratio of 43, and significant cash reserves.

stockstotrade.com3 min